A pathophysiologic approach to managing hyperlipemia.
Hyperlipemia is one of several risk factors for premature ischemic vascular disease. It usually represents a primary, lifelong metabolic disorder and control requires changes in life-style. These include a modification of diet (commonly caloric, cholesterol and saturated fat restriction), elimination of smoking and hypertension and, frequently, drug therapy. Drugs can attack endogenous triglyceride overproduction, lipoprotein lipase deficiency or defective remnant uptake, and can decrease cholesterol production and accelerate cholesterol degradation.
D000328:Adult; D002792:Cholestyramine Resin / Q000627:therapeutic use; D002994:Clofibrate / Q000627:therapeutic use; D003327:Coronary Disease / Q000517:prevention & control; D005260:Female; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy / Q000235:genetics / Q000503:physiopathology / Q000517:prevention & control*; D050356:Lipid Metabolism; D008071:Lipoprotein Lipase / Q000172:deficiency; D008099:Liver / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D009539:Nicotinic Acids / Q000627:therapeutic use; D012855:Sitosterols / Q000627:therapeutic use; D013974:Thyroxine / Q000627:therapeutic use; D014280:Triglycerides / Q000096:biosynthesis / Q000097:blood
D009539:Nicotinic Acids; D012855:Sitosterols; D014280:Triglycerides; D002792:Cholestyramine Resin; D008071:Lipoprotein Lipase; D002994:Clofibrate; D013974:Thyroxine